3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
96
Stomach Neoplasms
53
Rectal Neoplasms
49
Pancreatic Neoplasms
42
Colonic Neoplasms
34
Esophageal Neoplasms
30
Neoplasm Metastasis
28
Neoplasms
23
Adenocarcinoma Of Esophagus
19
Adenocarcinoma
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Lymphoma, Large B-Cell, Diffuse
7
Gallbladder Neoplasms
7
Biliary Tract Neoplasms
7
Esophageal Squamous Cell Carcinoma
6
Carcinoma, Non-Small-Cell Lung
6
Ovarian Neoplasms
5
Liver Neoplasms
5
Head and Neck Neoplasms
5
Cholangiocarcinoma
5
Recurrence
4
Lymphoma, Non-Hodgkin
4
Gastrointestinal Neoplasms
4
Carcinoma, Hepatocellular
4
Breast Neoplasms
4
Bile Duct Neoplasms
4
Peritoneal Neoplasms
3
Pancreatic Adenocarcinoma
3
Leukemia
3
Fallopian Tube Neoplasms
3
Interventions
Lenalidomide
3
Bortezomib
3
Dexamethasone
2
vandetanib
1
umbralisib
1
ublituximab
1
marizomib
1
durvalumab
1
carotuximab
1
avelumab
1
Zoledronic Acid
1
Vitamin D
1
Transplantation, Autologous
1
Tamoxifen
1
Standard of Care
1
Practice Guidelines as Topic
1
Palliative Care
1
Oxaliplatin
1
Melphalan
1
Leucovorin
1
Irinotecan
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Filgrastim
1
Cyclophosphamide
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Disease Progression
×
Oxaliplatin
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts